Published in:
18-09-2021 | Probiotics | Original Article
High-intensity interval training with probiotic supplementation decreases gene expression of NF-κβ and CXCL2 in small intestine of rats with steatosis
Authors:
Saba Mohammadi, Fatemeh Rostamkhani, Shahin Riyahi Malayeri, Hossein Shirvani
Published in:
Sport Sciences for Health
|
Issue 2/2022
Login to get access
Abstract
Purpose
The aim of this study was to investigate the effects of high-intensity interval training (HIIT) with probiotic supplementation (Lactobacillus rhamnosus GG) on gene expression of NF-κβ and CXCL2 in small intestine of rats with hepatic steatosis (induced by tetracycline).
Methods
Forty male Wistar rats (200 ± 20 g) were randomly divided into five groups of (n = 8 in each group): healthy control (HC), hepatic steatosis (HS), HS + HIIT, HS + probiotic (Pro) 5. HS + HIIT + Pro. Tetracycline was gavage at a dose of 140 mg/kg, for 7 days, to induce hepatic steatosis. The HIIT performed 5 sessions per week for 5 weeks on the rodent treadmill. Probiotic groups received 109 CFU/ml of Lactobacillus rhamnosus GG by oral gavage for 5 weeks (daily). ALT and AST were measured to confirm of HS. NF-κβ and CXCL2 genes were measured by Real-Time PCR in small intestine (jejunum).
Results
The results showed that there was a significant difference in gene expression of NF-κβ and CXCL2 (jejunum) between groups (p < 0.001). NF-κβ and CXCL2 mRNA levels in the steatosis group were greater than healthy controls (p < 0.05), while probiotic and HIIT groups had a lower intestinal NF-κβ and CXCL2 mRNA compared to steatosis group (p < 0.05).
Conclusions
Probiotic supplementation with HIIT leads to optimal cellular adaptation and the lower expression of NF-κβ and CXCL2 in the intestinal tissue of rats with fatty liver (steatosis). Due to the role of NF-κβ in regulation of apoptotic genes and proinflammatory cytokines, as well as the effect of CXCL2 on metabolism, insulin function and inflammatory responses, it seems that HIIT and probiotic may be effective in controlling fatty liver and gastrointestinal diseases.